| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Comparison of Alternative Network Meta-Analysis Methods in the Presence of Nonproportional Hazards: A Case Study in First-Line Advanced or Metastatic Renal Cell Carcinoma
|
Cope, Shannon
|
|
|
26 |
4 |
p. 465-476
|
artikel
|
| 2 |
A Conceptual Framework for Life-Cycle Health Technology Assessment
|
Pham, Thi Hao
|
|
|
26 |
4 |
p. 612-613
|
artikel
|
| 3 |
An Analysis of Accessibility of Representative Psychotropic Medicine From the World Health Organization Model List of Essential Medicines in Developing Countries With Different Income Levels
|
Shi, Yangfan
|
|
|
26 |
4 |
p. 528-535
|
artikel
|
| 4 |
Approaches to the Assessment of Clinical Benefit of Treatments for Conditions That Have Heterogeneous Symptoms and Impacts: Potential Applications in Rare Disease
|
Murray, Lindsey T.
|
|
|
26 |
4 |
p. 547-553
|
artikel
|
| 5 |
Author Reply
|
Kirwin, Erin M.
|
|
|
26 |
4 |
p. 614-616
|
artikel
|
| 6 |
Between-Hospital and Between-Physician Variation in Outcomes and Costs in High- and Low-Complex Surgery: A Nationwide Multilevel Analysis
|
Salet, Nèwel
|
|
|
26 |
4 |
p. 536-546
|
artikel
|
| 7 |
Copyright/Subscription
|
|
|
|
26 |
4 |
p. v
|
artikel
|
| 8 |
Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison Study
|
Li, Xiao
|
|
|
26 |
4 |
p. 508-518
|
artikel
|
| 9 |
Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping
|
Yang, Mo
|
|
|
26 |
4 |
p. 487-497
|
artikel
|
| 10 |
Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View
|
Do, Ngoc
|
|
|
26 |
4 |
p. 477-486
|
artikel
|
| 11 |
Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised
|
Acaster, Sarah
|
|
|
26 |
4 |
p. 567-578
|
artikel
|
| 12 |
Editorial Board
|
|
|
|
26 |
4 |
p. vi
|
artikel
|
| 13 |
Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Step Forward
|
Ghabri, Salah
|
|
|
26 |
4 |
p. 447-448
|
artikel
|
| 14 |
Illustrating Emerging Good Practices for Quantitative Benefit-Risk Assessment: A Hypothetical Case Study of Systemic Biologic Treatments for Plaque Psoriasis
|
Lackey, Leila G.
|
|
|
26 |
4 |
p. 519-527
|
artikel
|
| 15 |
Interaction Effects in Health State Valuation Studies: An Optimal Scaling Approach
|
Jonker, Marcel F.
|
|
|
26 |
4 |
p. 554-566
|
artikel
|
| 16 |
Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification
|
Marquina, Clara
|
|
|
26 |
4 |
p. 498-507
|
artikel
|
| 17 |
Mapping Studies to Estimate Health-State Utilities From Nonpreference-Based Outcome Measures: A Systematic Review on How Repeated Measurements are Taken Into Account
|
Oliveira Gonçalves, Ana Sofia
|
|
|
26 |
4 |
p. 589-597
|
artikel
|
| 18 |
Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies
|
Syeed, M. Sakil
|
|
|
26 |
4 |
p. 598-611
|
artikel
|
| 19 |
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force
|
Tervonen, Tommi
|
|
|
26 |
4 |
p. 449-460
|
artikel
|
| 20 |
Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: The Case of Switching to High-Dose Influenza Vaccine for Dutch Older Adults
|
Zeevat, Florian
|
|
|
26 |
4 |
p. 461-464
|
artikel
|
| 21 |
Reviewer Acknowledgment
|
|
|
|
26 |
4 |
p. 441-446
|
artikel
|
| 22 |
Suitability of Preference Methods Across the Medical Product Lifecycle: A Multicriteria Decision Analysis
|
Veldwijk, Jorien
|
|
|
26 |
4 |
p. 579-588
|
artikel
|
| 23 |
Table of Contents
|
|
|
|
26 |
4 |
p. i-iv
|
artikel
|
Tijdschrift beschrijving